ASML Financial Research Report

Disclaimer: This content reflects the views of the author(s) as of the date indicated and is for educational and informational purposes only. It is not investment advice. Do your own due diligence with a licensed financial advisor before making any investment decisions.

Latest Quarter Earnings Summary#

ASML's latest earnings (Q3 2025) showed stable results with net sales of €7.516 billion (virtually flat from €7.467 billion in Q3 2024) and a gross margin of 51.6% (up from 50.8% a year ago). Net income came in at €2.125 billion, roughly unchanged from €2.1 billion in the prior-year quarter, with EPS of €5.49 (vs €5.28 in Q3 2024). Importantly, new system sales volume was lower (66 new lithography systems sold in Q3 2025 vs 106 in Q3 2024), but this was offset by a richer product mix (EUV tools contributed strongly) such that revenue held steady. Net bookings - a key indicator of future demand - were €5.4 billion, more than double the year-ago bookings of €2.6 billion and slightly above analyst expectations, signaling robust forward demand.

ASML's outlook remains cautiously optimistic. The company reiterated full-year 2025 guidance for ~15% sales growth (to around €32.5 billion) with ~52% gross margin. For Q4 2025, ASML expects a seasonal revenue uptick to €9.2-9.8 billion with gross margin 51-53%. Notably, management warned that China sales are expected to drop significantly in 2026 after very strong contributions in 2024-2025 (China was ~46% of sales in 2024 and ~33% so far in 2025). This decline reflects tightening export controls and a normalization after a demand pull-in, but ASML still does not foresee 2026 total revenue falling below 2025 levels. Meanwhile, demand related to AI and advanced logic remains a tailwind - ASML is seeing "continued positive momentum" from investments in AI chips, benefiting both leading-edge logic (e.g. TSMC for GPUs) and advanced memory (e.g. HBM for AI). ASML's CEO highlighted that EUV adoption is progressing well (including shipments of the first High-NA EUV prototype and advanced packaging lithography tools). Overall, the quarter was in line with guidance, and the company maintains a confident long-term outlook despite near-term China headwinds.

ASML also updated its capital returns: it declared an interim dividend of €1.60 per share to be paid in Nov 2025, and it continued share buybacks with €148 million repurchased in Q3 (cumulative €5.9 billion repurchased under the 2022-2025 program). Management noted it will likely not complete the full €12 billion buyback authorization by end-2025 and intends to announce a new program in January 2026. This ongoing return of cash underscores ASML's strong free cash flow generation and shareholder-friendly policy.

(Sources: ASML Q3 2025 results press release; Reuters summary.)

Business Model#

Core Business & Revenue Streams: ASML is the world's leading supplier of lithography equipment - the machines used to imprint circuit patterns onto silicon wafers in chip manufacturing. Its flagship products are photolithography scanners, notably its exclusive Extreme Ultraviolet (EUV) lithography systems (critical for sub-7nm logic chips) and its Deep Ultraviolet (DUV) systems (used for a wide range of semiconductor nodes). ASML's revenue comes from two main sources: (1) New lithography system sales, and (2) Installed Base Management (services & upgrades). In 2024, new system sales accounted for roughly 77% of revenue (€21.77 billion out of €28.26 billion), while service and field option sales (maintenance contracts, spare parts, and performance upgrades on existing machines) contributed about 23% (€6.49 billion). The pie chart below illustrates this split:

Figure: ASML 2024 Revenue Breakdown - ~77% from new equipment sales vs ~23% from service/upgrades.

Within new system sales, ASML earns income from different product lines: EUV scanners (the most expensive at ~$150 million+ each) have grown to ~40-50% of new system revenue in recent years, while the remainder comes from DUV immersion scanners, DUV dry scanners, and special metrology/inspection systems. For example, in 2020 ASML sold 31 EUV systems generating €4.5 billion (~32% of 2020 sales), and this mix has increased as more chipmakers adopt EUV for advanced nodes. Services revenue (Installed Base Management) is a stable, high-margin source, growing with the cumulative installed base of machines - in 2024 it reached €6.5 billion, up ~15.5% YoY, as customers continued to purchase software enhancements, maintenance, and productivity upgrades to extend the life and output of their expensive tools.

Customer Base and Volume: Unlike consumer-facing companies, ASML has a small number of very large customers- essentially all the major semiconductor manufacturers. Its top customers include leading logic foundries and IDMs such as TSMC, Samsung Electronics, Intel, and SMIC, as well as memory chipmakers like SK Hynix, Micron, and Samsung (for DRAM/NAND). In total, ASML's customer count is on the order of a few dozen fabs worldwide - it sells to every chipmaker that requires advanced lithography, which might be ~60-70 companies globally (including smaller fabs), but a handful of big players drive the bulk of orders. For instance, in 2022, TSMC, Samsung, and Intel collectively accounted for a significant portion of ASML's revenue (TSMC alone has been estimated around ~30% in some years). China's share surged in 2024 as multiple Chinese fabs (like SMIC and YMTC) bought older-generation tools in bulk.

ASML ships a limited number of machines each year due to their complexity and cost. For perspective, in 2024 it sold 380 new lithography systems (44 of which were EUV, 336 DUV/other) and 38 used/refurbished systems. This volume (418 total systems) was actually lower than 2023's 449 systems, reflecting a slight industry downturn, but the average selling price (ASP) per system has risen with a richer mix of EUV. A decade ago, ASML's ASP for new systems was around €25 million; in recent quarters it's substantially higher - for example, in 2023 the blended ASP was roughly €52 million (total new system sales €21.8B/421 units) as EUV tools (priced >€150 M each) made up a larger share. The installed base is also sizable: ASML has thousands of systems in the field (by 2020, over 1,200 DUV scanners and ~100 EUV units cumulatively) which generate recurring service revenue. Each EUV machine comes with a service contract and ongoing upgrade cycle (e.g. source power improvements) - a strong annuity-like stream.

Competitive Moat: ASML enjoys a formidable moat rooted in technological monopoly and ecosystem lock-in. It is literally the only company in the world that can produce cutting-edge EUV lithography tools - a result of decades of R&D investment (~€6 billion spent to develop EUV) and a complex supplier network (e.g. Zeiss for the ultra-precise mirrors) that would be nearly impossible for a new entrant to replicate. In DUV lithography, ASML also holds the largest market share (~60-70%), with only two much smaller competitors (Nikon and Canon) focused on older technology. Nikon, the former rival in high-end lithography, has essentially fallen behind - it no longer produces cutting-edge scanners for leading-edge nodes after the 193nm immersion era, ceding that market entirely to ASML. This near-monopoly in leading lithography gives ASML significant pricing power and deep integration with customers. ASML's tools are mission-critical - chipmakers cannot produce advanced chips without ASML's machines, making ASML an indispensable supplier. Furthermore, ASML's know-how spans hardware, specialized light sources, resist chemistry optimization, and software (its computational lithography and metrology products enhance yield). The ecosystem effect is strong: ASML collaborates closely with customers and materials suppliers to continuously improve yields, creating high switching costs. A customer designing a 3nm process with ASML's EUV tools, Twinscan platforms, and YieldStar metrology is deeply invested in ASML's ecosystem. The company also fiercely protects its IP (e.g. it pursued and settled a patent dispute with Nikon in 2018, and it closely guards against any technology leakage, such as a recent incident of an ex-employee allegedly stealing data for a Chinese firm). All these factors form a formidable moat. In short, ASML is often described as a "one-of-a-kind monopoly" in a critical segment of the semiconductor supply chain, which is why its profit margins and returns are extraordinarily high.

Key takeaway: ASML's business model is selling essential "picks and shovels" to chipmakers, specifically lithography systems that have no close substitutes. Its revenue is diversified across product lines (EUV vs DUV) and supplemented by recurring service income. With a near-monopoly in EUV and a dominant position in DUV, ASML's moat is secure - it would take any rival many years and tens of billions in R&D to even attempt to catch up, as evidenced by the lack of any viable competitor in EUV lithography.

Headwinds & Risks#

Short-Term/Cyclical Headwinds: In the near term (next 1-2 years), ASML faces cyclical and macroeconomic pressures that could temporarily impact its business:

• Semiconductor Demand Cycles: The chip industry is notoriously cyclical. Downturns in end-market demand (PCs, smartphones, etc.) or inventory corrections can lead chipmakers to delay capacity expansion, reducing orders for ASML's tools. For instance, in late 2022 into 2023, a slump in memory chip prices and smartphone demand caused some ASML customers to push out tool deliveries. ASML's 2024 revenue was almost flat (+2.5%) after years of growth, reflecting a broader chip downturn. Such cycles are temporary, but ASML's quarterly orders and revenue can fluctuate significantly with the capex cycles of a few large customers.

• Export Controls & Geopolitics: Geopolitical tensions - particularly the U.S.-China tech war - present short-term volatility. The Dutch government (under pressure from the U.S.) has imposed export restrictions on ASML's most advanced tools to China. Since 2019, ASML has been barred from selling EUV scanners to China, and in 2023 the Netherlands expanded curbs to certain advanced DUV models. ASML can still sell older DUV to Chinese fabs, which led to a surge of orders in 2024-25 as Chinese customers rushed to stockpile tools. However, as noted, China sales are expected to drop sharply in 2026 due to these restrictions and the prior pull-forward of demand. Politically-driven swings in access to China's market act as a short-term headwind (China was ~€8.5B of ASML's €28.3B sales in 2024, so a decline will create a growth gap in 2026). That said, ASML management believes this is a normalization rather than a permanent loss - China represented unusually high demand in 2024-25 that will "normalize" lower. Also, ASML's backlog from other regions (Taiwan, Korea, U.S., Europe) is strong enough that they expect 2026 sales at least flat vs 2025 despite the China fall-off.

• Supply Chain Constraints: ASML's ability to ship tools on time can be hampered by supply bottlenecks. Its machines involve thousands of components (optics, electronics, precision mechatronics), so shortages in any critical component (like high-end lasers or lens materials) could delay production. In early 2022, a fire at one of ASML's suppliers (Berlin factory of a component supplier) threatened to impact tool shipments by a few hundred million euros (though ASML managed to mitigate most of it). Any similar disruptions, or general supply chain tightness, are short-term risks that can shift quarterly revenue from one quarter to the next.

• Economic Slowdowns: A broader macroeconomic slowdown or recession can indirectly reduce demand for electronics (and hence chips and fab equipment). For example, rising interest rates and inflation have tempered consumer electronics spending recently, which filtered through to more cautious capex by chipmakers in 2023. If global GDP weakens significantly, chip companies may defer expansion plans, hitting ASML's near-term growth. However, such slowdowns typically delay orders rather than cancel them - the secular demand for semiconductors tends to resume once the economy improves.

In summary, short-term headwinds like cyclical downturns and export restrictions may cause some lumpy results or modest growth pauses (as seen in 2019 and 2024), but ASML has so far weathered these with only temporary impacts. The company's robust order backlog and broad customer base across logic and memory help cushion cyclical swings.

Long-Term/Secular Risks: Over the longer term (5-10+ years), ASML faces several strategic risks that could permanently influence its business:

• Technological Disruption or Alternatives: ASML's dominance relies on optical lithography remaining the key process for chipmaking. A radical new technology that supplants photolithography could erode ASML's core business. Potential alternatives often discussed include next-generation lithography methods like electron-beam direct-write, nanoimprint lithography, or even completely new computing paradigms (like quantum computingor 3D chip architectures that reduce reliance on 2D litho scaling). So far, none of these have proven viable at scale - optical lithography (193nm immersion and now EUV 13.5nm) continues to be extended with ASML's innovations. ASML is already developing High-NA EUV (a next-gen EUV tool with a higher numerical aperture lens to further shrink features) expected by 2025-2026 to enable <2nm nodes. This suggests ASML can likely maintain lithography leadership through the foreseeable future. However, if a non-optical method eventually achieves high-volume manufacturing at smaller geometries, it could threaten ASML's monopoly. This is a distant but existential risk. (Notably, ASML is actively involved in exploring beyond-EUV options and has a track record of pivoting - e.g., decades ago it researched X-ray lithography before EUV became viable).

• Geopolitical Decoupling & Loss of Markets: A more permanent splitting of the semiconductor supply chain into geopolitical blocs could constrain ASML's full market potential. If China (the world's largest chip consumer) cannot purchase ASML's top tools indefinitely, ASML loses a growth avenue (it can still sell older tools there, but those are lower-margin and eventually even DUV may be restricted further). In a worst-case scenario, China might succeed in developing its own lithography equipment for mature nodes - China's SMEE has primitive 90nm lithography tools today, far behind ASML, but over a decade they could potentially narrow the gap for less advanced processes. While it's unlikely China can replicate EUV in any reasonable timeframe (ASML's CEO has suggested it would take many years and international cooperation for anyone else to build an EUV scanner), a self-sufficient Chinese tool industry is a long-term competitive threat. Also, prolonged trade restrictions might push China to invest heavily in alternatives (like multi-patterning older tech or other techniques) reducing reliance on ASML. Outside China, geopolitical factors could cause ASML to shift supply chains or manufacturing (e.g., the U.S. pushing for more tool production domestically) which could add cost or complexity.

• Customer Consolidation or Insourcing: The semiconductor industry has consolidated - e.g., memory has just a few players, logic foundry is dominated by TSMC. If one of ASML's major customers significantly cuts back or faces trouble, ASML's sales could be permanently impacted. For instance, if Intel's market share in leading-edge logic continues to erode, its lithography orders might never recover (though TSMC or Samsung tends to pick up the slack, so industry demand overall remains). Another angle: a large customer insourcing lithography development - this is highly improbable given the cost and ASML's head start, but a giant like Intel once attempted more control by investing in ASML (Intel, Samsung, and TSMC each took a ~15% stake in ASML in 2012 to fund EUV R&D, rather than doing it themselves). The result only strengthened ASML's collaborative model. Thus, customer-related long-term risk is moderate.

• Execution & Saturation: ASML's long-term growth also depends on continued device scaling. Physical limits in chip shrinking could slow lithography demand - e.g., if Moore's Law significantly decelerates, fabs might buy fewer cutting-edge tools or extend tool lifetimes. ASML's EUV is enabling the current roadmap (~2nm), but beyond that, the industry might shift to stacking (chiplets, 3D packaging) more than shrinks. ASML is addressing this by entering advanced packaging lithography (they shipped their first dedicated tool for chip packaging in 2025). Still, if transistor miniaturization enters a long plateau, lithography tool sales might plateau too - not vanish, but growth could slow permanently.

• Cost Inflation & Complexity: Each new generation of lithography is exorbitantly costly. EUV tool development took decades; High-NA EUV is extremely complex. If R&D costs start outweighing the market's willingness to pay, ASML's returns could diminish. For example, an EUV tool costs ~$150M; a High-NA EUV might cost well over $300M. If only a couple of customers adopt it, ASML must ensure it recoups costs. Thus far, demand is there (ASML has orders for High-NA from multiple customers for 2025+), but the risk is that technological complexity or delays (e.g., if High-NA faces issues) could permanently strain ASML's growth or allow an alternative solution to catch up.

In summary, permanent risks to ASML revolve around technological shifts (a new paradigm replacing optical lithography), geopolitical realignment (losing access to a portion of the market), and the eventual slowdown of Moore's Law. None of these are imminent threats - ASML's leadership position looks secure for at least the next several years (even critics acknowledge no viable alternative to ASML's tools through 2030). However, investors should monitor signs of these secular changes. ASML itself remains proactive: it continuously innovates (investing ~€3-4B in R&D annually), and it advocates on geopolitical matters (working with governments to navigate export rules).

Overall, while short-term headwinds may create bumps, ASML's long-term narrative as the linchpin of chip fabrication remains intact. The biggest long-run risk - a displacement of lithography - appears low probability in the next decade, given industry consensus that "lithography will remain at the heart of customer innovation" and ASML's own confidence in extending its roadmap.

Cost Structure#

ASML's cost structure combines high fixed costs (for R&D, engineering, and manufacturing overhead) with variable costs tied to machine production. Understanding its costs provides insight into margins and how they behave in different conditions:

• Cost per Machine (COGS per unit): ASML's machines are extremely complex, so each unit has a high bill of materials and assembly cost. For example, an EUV scanner contains unique components (specialized lasers, ultra-flat mirrors, vacuum chambers) sourced from a network of suppliers like Zeiss. The cost of goods sold (COGS)includes these materials and direct labor for assembly. ASML doesn't disclose cost per unit explicitly, but we can infer margins: in 2024, gross margin was ~51.3%, meaning roughly half of the sales price is gross profit. If a new EUV sells for ~$150 million, perhaps ~$75 million is cost. Importantly, COGS has a large fixed-cost absorption element - ASML's factories must run close to capacity to spread overhead. When volume drops, unit cost rises (hurting gross margin), and vice versa. This is why gross margin fluctuates with volume: e.g., in the softer 2019, GM was ~44.7%, whereas in boom years like 2021, GM reached 52.7%. ASML also continuously works to reduce unit costs via learning-curve effects (especially for new products like EUV where yield improvements in manufacturing can lower cost). For instance, ASML significantly improved the source reliability and production efficiency of EUV tools over time, which helped raise EUV gross margins closer to corporate average by 2021-2022 (initially EUV tools were barely breakeven in cost). So while each machine has high variable cost, scale economies are vital - marginal cost declines as production volume increases and processes mature.

• Labor Expenses: ASML employs over 44,000 people globally as of 2025. A large portion are highly skilled engineers (for R&D and customer support) and manufacturing specialists. Labor costs appear in both COGS (factory workers) and operating expenses (R&D engineers, SG&A staff). In 2024, ASML's total operating expenses were about €5.47 billion, of which the majority is R&D (€4.63 billion in 2024 per Yahoo Finance data) and the rest SG&A (~€0.84 B). Much of these expenses are essentially labor (salaries, benefits) and are relatively fixed - ASML doesn't lay off R&D staff in a slow quarter; it views R&D as vital and tends to increase it consistently (e.g. R&D spend grew from ~€0.9B in 2015 to ~€4.6B in 2024). Thus, labor costs (especially R&D) are fixed costs that ASML carries through downturns, impacting operating margins but preserving long-term competitiveness. On the production side, ASML's workforce has grown to meet demand, but management is cautious to avoid over-hiring cyclically - they use subcontractors in manufacturing that can be adjusted as needed. Still, skilled labor is a critical resource for ASML and not easily variable; the company invests heavily in talent retention and recruitment (particularly in the Netherlands and in tech hubs worldwide).

• R&D and Fixed Overhead: R&D is by far ASML's largest expense category (in 2021-2024, R&D was ~12-16% of sales each year). These are fixed costs aimed at future products: e.g., developing High-NA EUV, next-gen DUV improvements, new software, etc. R&D does not scale with quarterly tool shipments - it's a strategic investment. Similarly, ASML has significant capital expenditures on its own facilities (cleanrooms, demo labs) - though these are modest relative to revenue (CapEx in 2024 was €2.61B, about 9% of sales). Depreciation of these facilities (and amortization of capitalized development costs, if any) is another fixed cost. Manufacturing overhead(running cleanrooms, maintaining precision equipment to assemble tools) is also largely fixed. For example, ASML's Eindhoven and Veldhoven factories must be maintained and climate-controlled regardless of whether they ship 30 or 50 tools in a quarter. This fixed-cost leverage means ASML's profitability improves dramatically when volume is high - overhead per machine goes down. Conversely, in periods of low demand, ASML's gross and operating margins compress because these fixed costs get spread over fewer units. We saw this in 2019: ASML shipped 229 new systems vs 207 in 2018, but those included some lower-end models and operating profit margin fell as certain fixed costs remained (2019 op margin ~24%, down from ~29.5% in 2018, partly due to EUV R&D and overhead still ramping).

• Material and Component Costs: A significant variable cost is the advanced components ASML buys. This includes precision lenses and mirrors (sourced exclusively from Carl Zeiss SMT in Germany - ASML even took a 24.9% stake in Zeiss SMT to secure this supply), lasers (from companies like Cymer, which ASML acquired in 2013 for DUV lasers, and Gigaphoton or Trumpf for EUV light sources), sensors, and ultra-clean ceramics, among others. These parts are expensive and can even fluctuate in cost if supply is tight. However, ASML often has long-term supply agreements; for instance, it co-invests with suppliers to ensure capacity (the Zeiss stake is a prime example). So while materials are a variable cost per unit, ASML has some control - it is more constrained by availability than price swings, since few alternatives exist and it effectively single-sources from aligned partners.

• Advertising & Marketing: ASML's marketing expenses are relatively minimal in the context of its financials. This is a B2B business where sales are relationship-driven and highly technical. ASML does not need mass-market advertising; their "marketing" is mainly participating in industry conferences, hosting investor days, and engaging in one-on-one negotiations with the handful of chip manufacturers. Selling expenses (part of SG&A) include things like sales engineers, customer training, and after-sales support infrastructure. In 2024, total SG&A was around €0.84B (just ~3% of sales) - indicating how low marketing/sales spend is relative to revenue (compare that to R&D at ~16% or COGS ~49%). We can infer pure advertising spend is negligible; ASML's brand and market position carry weight automatically in the industry (if you're a chipmaker, you already know ASML - "marketing" is built-in through technical reputation). One exception might be employer branding - ASML invests in outreach to attract engineers (for example, sponsoring tech events, local initiatives, even sports in the Brainport Eindhoven region) - but again these costs are small.

• Most Significant Costs: The most significant costs for ASML are R&D and manufacturing costs (materials + overhead). In terms of the P&L, COGS (materials, manufacturing labor, factory costs) was ~49% of revenue in 2024, and R&D was ~16%. Together, these dominate the cost structure. To break it down: Out of €28.3B revenue in 2024, COGS was ~€13.8B, R&D ~€4.6B, SG&A ~€0.8B. So materials/components (~€7-8B) and personnel (manufacturing + R&D staff compensation) are the bulk of expenses. Another way to see significance: Gross margin (which reflects materials and production efficiency) is ~50%, whereas operating margin is ~32%. The 18-point drop is almost entirely R&D and SG&A. Thus, material costs and R&D are the critical cost levers for ASML's profitability.

• Cost Trends Over Time & in Different Environments: Over the past decade, ASML's cost structure has scaled but also evolved with product mix. We have seen gross margin rise from mid-40s% to over 50% as volume grew and EUV production matured. During boom times (e.g. 2021's 33% revenue growth), ASML's fixed cost absorption was excellent - gross margin hit 52.7%, and operating margin over 30%. In slower times, margins dip (2019 GM 44.7%, op margin ~24% as noted). ASML tends to maintain R&D through cycles, which means in a downturn the operating margin compresses more (as happened in 2019 when net income was flat on higher R&D, and in 2023 when R&D rose ~20% despite slower sales). In high-demand periods, that R&D is rewarded with outsized profit growth.

In different economic conditions, ASML's costs behave as follows: In a downturn, it has limited ability to cut short-term costs - it won't slash R&D (doing so would jeopardize future tech leadership), and it has commitments to suppliers (for long lead-time components) that it generally upholds to preserve relationships. It may slow new hiring or use up inventory (reducing purchasing temporarily), but fundamentally costs are mostly fixed or strategic. This can lead to temporary margin compression, as seen in the slight EPS dip in 2022 despite revenue growth (~flat net income due to heavy R&D and some one-time charges). In an upturn, those fixed costs become a boon - revenue can surge without a proportional rise in R&D or SG&A, boosting margins and returns (e.g., net income jumped ~65% in 2021 on 33% sales growth).

Bottom line: ASML's cost structure is characterized by high fixed costs (R&D, overhead, highly skilled labor) and substantial variable costs per machine (specialized components). The most influential costs are the technology investments (R&D) and the precision manufacturing costs. Over time, ASML has improved its cost per unit through learning curve and volume, which, combined with its pricing power, has steadily lifted gross margins. It spends aggressively on R&D regardless of cycles, reflecting a long-term focus. This means in lean years ASML's earnings may dip as it "bites the bullet" on maintaining costs, but in growth years it reaps the rewards of scale. This approach has been effective, as evidenced by strong profitability across cycles and sustained technological leadership.

(Sources: ASML financial statements; ASML press releases on R&D and share buybacks.)

Management & Governance#

Executive Team & Board (Current and Historical): ASML's management team blends long-term company veterans with new leadership for its next phase. As of 2025, Christophe Fouquet is President & CEO (he succeeded Peter Wennink in 2025) . Fouquet has been with ASML for years (he previously led EUV product marketing and corporate strategy) and was a natural internal successor when Wennink retired. Roger Dassen is the CFO (since 2018) - he was formerly a partner at Deloitte and has overseen ASML's finance during its recent growth spurt. The broader executive team includes Martin van den Brink (a 35+ year ASML veteran who served as CTO and was instrumental in EUV development) - van den Brink is considered a "founding father" of ASML's technology and remains on the Board of Management as Vice Chairman. Other key executives are Fredrick Schneider (Chief Operations Officer) and the heads of product sectors like EUV, DUV, etc. On the Board of Directors (Supervisory Board), Nils Andersen serves as Chairman. The board includes industry and finance figures; for example, former executives from Dutch tech firms and international experts. Importantly, ASML's governance structure is two-tier (common in the Netherlands): the Board of Management (executives) runs day-to-day, while the Supervisory Board oversees and advises. ASML's historical leadership is notable: the company's previous CEO, Peter Wennink (CEO from 2013-2025), was actually ASML's CFO before taking the helm and had joined ASML in 1999. Wennink, along with van den Brink, guided ASML through the critical EUV investment years. ASML was originally founded as a joint venture by Philips and ASM International in 1984 - its early leaders came from those parent companies (e.g., co-founder and first CEO Arthur del Prado from ASM). Though no founders are actively managing the company now, the spirit of long-term innovation set by them continues.

Overall, ASML's top management has extensive company tenure. Many have spent decades at ASML, which provides continuity. There is also continuity in strategy: Peter Wennink was succeeded by an internal leader (Fouquet) to ensure a smooth transition - similar to how Wennink himself continued the work of his predecessor Eric Meurice in pushing EUV. The company's culture has been described as "technology-driven and collaborative", and much of the senior team either grew up in that culture or were brought in to support it.

Management Track Record & Transparency: ASML's management has generally delivered on the promises it makes to investors. For example, several years ago ASML laid out a 2020-2025 growth scenario (at Investor Day) predicting significant revenue expansion; so far they have achieved much of it (with ~€28B sales in 2024 and targeting €30-35B in 2025). When it comes to product development goals, management has been fairly transparent about challenges. EUV is a case in point: it was delayed for years beyond initial hopes, but ASML kept investors informed through regular updates on source power, throughput milestones, etc. It did not hide the fact that EUV was consuming massive R&D and that initial adoption would be slow. Now, EUV is paying off, as management foresaw. Analysts often ask tough questions on ASML's earnings calls about things like order push-outs or gross margin pressure; management (Wennink and Dassen in recent years) have answered candidly. For instance, they openly discussed how in 2023 some memory customers delayed shipments and how that affected the mix and margins, rather than obscuring it. ASML also provides mid-quarter updates when necessary, like pre-announcing if a significant event (supplier fire or new export rule) might alter their outlook. There's little evidence of ASML's management hiding problems - on the contrary, they tend to address issues directly (e.g., acknowledging the IP theft incident by a China-based employee in 2023 and reinforcing data security measures).

On analyst calls, ASML's management has a reputation for being straightforward and technically deep. Longtime CEO Peter Wennink was known for detailed explanations (he himself is an accountant by background but extremely knowledgeable on the tech as well). The new CEO Christophe Fouquet, coming from the technical side, similarly can answer in-depth on product timelines. They typically give comprehensive answers rather than evasive ones - for example, detailing how many EUV layers customers are using or what utilization rates look like, which not all companies would disclose in detail.

Management Stability and Integrity: The core leadership (van den Brink, Wennink, etc.) has been with ASML for decades, instilling confidence in their commitment. Turnover at the top has been low. The CFO position changed in 2018 when Roger Dassen took over (the prior CFO became a board member), but that was a planned succession. The supervisory board, too, includes stable figures like former CEO Eric Meurice who served on it after stepping down. There haven't been scandals involving management dishonesty or accounting irregularities. In fact, ASML is often cited for strong corporate governance among European tech firms.

There was one notable governance event: In 2012, ASML orchestrated a client co-investment program where TSMC, Intel, and Samsung took minority stakes in ASML (around 10% each) to help fund EUV R&D. This was done transparently and with shareholder approval, demonstrating management's creative approach to securing funds while aligning customer interests. It also showed management's alignment with shareholders - those stakes were later mostly bought back or diluted down, and ASML ensured that all other shareholders benefited through a synthetic buyback for equal treatment.

No significant accusations of integrity issues have been raised - for example, no regulatory investigations for fraud, etc. The only contentious issues have been industry-related (like patent fights with Nikon, or trade issues, not managerial wrongdoing). Simply put, management's credibility is high: when they set targets (like "€15 EPS by 2020" or "€5.5 dividend for 2021" etc.), they have hit or exceeded them.

Management & Shareholder Alignment (Value Alignment): The leadership at ASML appears to be well-aligned with shareholder interests, though not necessarily through extremely large personal stock ownership. Top executives do own ASML shares, but their stakes are relatively modest. For example, outgoing CEO Peter Wennink reportedly held only about 2,600 shares as of early 2024 - roughly $2.5 million worth, which is small relative to his tenure and compensation (meaning he likely sold shares over time as part of diversification or planned sales). However, ASML's management is compensated partly in stock and performance units, which vests based on long-term targets, so they have incentive to grow the business. More qualitatively, many of ASML's leaders have devoted their careers to the company - they are engineers and technologists motivated by achieving breakthroughs (the pride in making EUV happen), which aligns with creating shareholder value (since those breakthroughs have indeed translated to dominance and profits).

ASML's capital allocation under management has strongly favored shareholder returns once R&D needs are met. The company has dramatically increased dividends (e.g., doubling the dividend in 2021 to €5.50) and has ongoing share buyback programs. This suggests management is not hoarding cash or empire-building; instead, they return excess capital. Such actions indicate they aim to "earn more from growing the business than from compensation." For instance, the 2020-2022 €6B buyback and the current €12B program show management's confidence in ASML's future and a desire to boost EPS for remaining shareholders.

During short-term stock declines, ASML insiders have occasionally bought stock, though there isn't a strong pattern of heavy insider buying (mostly because the stock rarely gets cheap by conventional measures). But the consistent buybacks by the company itself effectively mean management is using corporate funds to repurchase shares when they see value. In early 2023, when ASML's stock dipped amid market rotation, the company accelerated buybacks, implicitly showing management's belief in undervaluation.

One area to observe is executive pay relative to performance. ASML's executive compensation includes long-term incentives tied to metrics like earnings growth and return on invested capital. Given ASML's stellar performance (the share price rose ~10x during Wennink's decade as CEO), those incentives likely paid out well - aligning management's wealth growth with shareholders'. The fact that ASML's shares have dramatically increased under management's tenure (1,000% total return over Wennink's term) speaks to management's effective execution and alignment with shareholder success.

In terms of governance checks, ASML's supervisory board provides oversight and includes independent members, which helps ensure management doesn't go off-track. There have been no public shareholder disputes or activist interventions, likely because management has been executing well and communicating transparently.

Integrity and Reputation: ASML's management has not been subject to integrity doubts in the way some companies have (no accounting restatements, no corruption probes, etc.). The company operates in multiple countries and adheres to strict export controls and compliance - any misstep there would be huge news, but ASML has navigated these issues carefully, often even erring on the side of caution with self-imposed restrictions until rules are clear. The only notable hiccup was the revelation in 2019 that ASML was a victim of intellectual property theft by a Chinese competitor some years prior (this happened under previous management around 2015, involving ASML's Silicon Valley software subsidiary). ASML responded openly, took legal action, and ultimately there was minimal damage beyond a settlement. This incident was not due to management malfeasance but an external party's wrongdoing. ASML's handling of it further solidified its management's commitment to protect shareholders' interests.

In summary, ASML's management and governance are considered strong and shareholder-friendly. The leadership team has deep company and industry experience, has delivered on strategic goals (like making EUV commercially successful), and has a history of returning value to shareholders (dividends and buybacks) while investing sufficiently in R&D. There is good continuity in succession (no abrupt CEO changes or strategy shifts) and good transparency with the market. The combination of technical vision (van den Brink and team), prudent financial management (Dassen, Wennink), and strategic foresight (Fouquet, etc.) has made ASML one of Europe's most respected tech companies. Stakeholders have generally not questioned their integrity - rather, management is often praised for its clarity and long-term orientation.

Shareholders & Capital Returns#

Ownership Structure & Top Shareholders: ASML has a widely distributed ownership with no single controlling shareholder. Its shares trade in both Amsterdam (AEX) and on NASDAQ, and the bulk of ownership is by large institutional investors (global asset managers, index funds). According to recent filings, the top shareholders are predominantly big U.S. and European investment firms. For instance, as of 2022, the largest holders included T. Rowe Price Associates (~2.7% stake), Capital Group (Capital World Investors) (~1.6%), Fisher Investments (~1.1%), BlackRock and Vanguard (through various index funds, each likely around 3-4% cumulatively though not always reported as one line item), and others like Morgan Stanley Investment Mgmt, WCM Investment Management, etc., each holding under 1%. No single shareholder owns more than ~3%. This means ASML is not under the sway of a founder or a government - it's truly a public company with a broad base.

Many top holders are passive index funds (e.g., as ASML is a member of the Euro STOXX 50 and NASDAQ-100, lots of index funds hold it). But there are active mutual funds and hedge funds as well - for instance, Capital Group's various funds (like EuroPacific Growth) have been long-term holders; Baillie Gifford (a growth-focused firm) has also been an investor in the past, and Fundsmith (Terry Smith's fund) has held ASML as a top position given its quality business profile.

In terms of shareholder voting and engagement: The key topics at recent shareholder meetings (AGMs) have included approving dividends, share repurchase authorizations, and board appointments. Large shareholders generally vote in line with management on these items, because management's proposals have been shareholder-friendly (e.g., increasing dividends 100% in 2022 got broad support). There haven't been activist campaigns or contentious votes in recent memory - proposals like executive compensation packages or share issuances have passed easily. For example, ASML routinely asks shareholders to authorize the Board to issue up to 5% new shares for flexibility (a common Dutch practice) - these have passed. Top shareholders like BlackRock and Vanguard typically vote for management's proposals in ASML's case, as there have been no governance red flags.

One notable voting situation: Share buyback approvals. European companies often need periodic shareholder approval to execute buybacks above certain thresholds. ASML's investors have strongly supported these. Additionally, when ASML did the 2012 customer co-investment program (issuing ~23% new shares to TSMC, Intel, Samsung in exchange for funding), it required shareholder approval. That vote passed with overwhelming support because management demonstrated the strategic benefit. (All shareholders got a form of compensation via a special cash return to mitigate dilution, which likely helped garner support).

In recent AGMs, some shareholders have raised ESG-related proposals (for instance, questions about ASML's environmental footprint or about export control ethics). Thus far, no separate shareholder resolutions on those topics have made it to a vote - they are usually addressed by management in the meeting and in sustainability reports. The large institutional investors have not put forward dissident resolutions; they seem satisfied with ASML's direction.

Capital Return Policy (Dividends & Buybacks): ASML has significantly ramped up capital returns over the past decade, reflecting its rising free cash flow.

• Dividends: ASML initiated a dividend in 2008 and has increased it consistently. In early years it was small (e.g., €0.40 per share in 2010). By mid-2010s it was ~€1-2.** and recently it has jumped. ASML doubled the dividend for 2021 to €5.50 (from €2.75 in 2020), and then increased it further to €5.80 for 2022 and €6.40 for 2023. These large hikes correspond to earnings growth and a policy of raising payout as net income rises. ASML doesn't have a fixed payout ratio target announced, but in practice the dividend has tracked roughly 20-40% of earnings. For example, 2023 EPS was €19.91 and dividend €6.40 (32% payout). The company usually declares an interim and a final dividend each year. Shareholders have readily approved these dividends - who would object to more cash? - and management has stated it intends to grow dividends in line with or faster than earnings when feasible. Dividends require a simple majority vote at the AGM, which they have obtained easily.

• Share Buybacks: ASML has used buybacks opportunistically and through multi-year programs. The current program (2022-2025) authorized up to €12 billion in repurchases. As of Q3 2025, ASML had repurchased €5.9 billion worth (about 9 million shares) under this program. Management noted they may not complete the full €12B by end-2025 given some constraints (possibly high share price or prioritizing capital for other uses), but they plan to start a new program in 2026. Looking back, ASML's buyback history over the last 10 years shows a steady reduction in share count:

  • In 2010-2012, ASML did modest buybacks.

  • In 2012, after the special customer investment, ASML had a synthetic buyback (returning €9 per share to non-participating shareholders) to offset dilution - effectively a one-time capital return.

  • 2016-2017: ASML had a €1.5B buyback program (it completed ~€0.9B of it by end-2017).

  • 2018-2019: It announced a €2.5B program (Jan 2018), and completed it by end-2019, repurchasing ~ASML shares at average ~€109. This retired roughly 2-3% of shares each year.

  • 2020-2022: A larger €6 billion program was launched (Jan 2020). Despite the pandemic, ASML continued it - by early 2022, they had finished it (ASML repurchased around €6B cumulative by end of 2021, as strong cash flow allowed acceleration).

  • 2022-2025: The current €12B program, as noted, is partially done and likely to roll into a new one.

These buybacks have been value-accretive - for example, ASML was buying heavily in 2020 when the stock fell briefly during COVID (~€200-300 levels), and again in 2022 when tech stocks dipped. The share count has come down from about 431 million shares in 2015 to ~388 million in 2025. That's nearly a 10% reduction, despite issuing some shares for employee plans. Long-term shareholders benefit from this enhanced EPS.

Top shareholders generally support buybacks because ASML has ample cash generation and limited M&A needs (it tends to acquire a company only rarely, like Cymer in 2013 for ~$2B, and smaller tech tuck-ins). There's been no opposition in votes to renewing buyback authorizations. Institutions like BlackRock and Capital Group, which often have policies favoring returns of excess cash, are likely pleased with ASML's balanced approach (invest in R&D first, then return cash).

Shareholder Voting & Topics: At ASML's 2023 AGM, some of the key items and outcomes were:

• Dividend approval: Passed with over 99% for.

• Share repurchase authorization: Passed (~98% for).

• Board re-elections: ASML's board members (e.g., the re-appointment of CEO to Board of Management, and various Supervisory Board members) typically receive >95% support, indicating shareholders trust the leadership.

• Executive compensation (remuneration policy): Passed with high support - ASML's performance and stock rise likely quell any investor concerns about pay being undeserved.

• Discharge of Management and Board: A Dutch annual formality releasing them from liability for the year's actions - always passed, indicating no serious shareholder accusations.

There was little controversy. Top shareholders like T. Rowe and Capital Group, known to vote against management if unhappy, have consistently voted with management here - reflecting satisfaction. We haven't seen activist proposals like splitting the company or demanding higher payouts, because ASML already operates efficiently and returns cash generously.

In summary, ASML's shareholder base is institutional and supportive. The largest holders have modest percentages but collectively institutions likely own well over 80%. They have executed their voting rights mainly in favor of management's strategy. The topics of most interest to them are perhaps ASML's guidance and technology updates rather than governance changes - the absence of activist agitation suggests they're content.

One thing to watch: if any government fund (like a sovereign wealth fund) or industry peer tried to take a big stake, that could influence votes. However, ASML's articles of association prevent unwanted control - any 20%+ stake would likely face Dutch/EU scrutiny given ASML's strategic importance. Also, the Dutch government has a golden share in ASML's predecessor (Philips) for certain decisions? Actually, not in ASML's case - but ASML is considered strategic, so a hostile take-over is improbable. Thus, no single shareholder can easily dictate the agenda - it's a collective voice.

Notable Value Investors' Trading History: Given ASML's strong fundamentals but high valuation, traditional value investors (à la Warren Buffett) haven't been prominent holders historically (Buffett's Berkshire has not invested in ASML as far as public filings show). However, many quality-focused investors (who often straddle value and growth) have owned ASML:

• Baillie Gifford (Scottish Mortgage Trust) owned ASML for many years as part of their global growth portfolio, likely buying in the 2010s and trimming as it became very large. They value its monopoly and secular growth.

• Fundsmith (Terry Smith) - an influential UK fund manager known for buy-and-hold of high-quality businesses - has ASML as a top 10 holding (he started buying around 2018-2019 at far lower prices). Terry Smith publicly discussed ASML as a unique franchise worth paying up for, essentially a Buffett-style "great company at a fair price." His fund's average cost might have been a few hundred euros; they have not sold and it's ~6% of their fund. They appear to still hold, believing ASML's prospects extend for many years (though the holding % may fluctuate with price).

• Lindsell Train (Nick Train, another UK quality investor) was reported to have ASML in some portfolios as well.

• Capital Group (while not a single investor, their Capital International funds often take long-term value-oriented approaches) - they increased stakes when ASML's price dipped, e.g., possibly adding in 2022's dip, and have held for the long haul.

• Hedge fund perspective: Growth-oriented hedge funds like Coatue, Tiger Global have at times held ASML during tech rallies but might trade in and out. Some 13F filings show Chase Coleman's Tiger Global held ASML a few years ago but it's not clear if still. Ken Fisher (Fisher Asset Management) as shown had about 1.1% stake by mid-2022 and he tends to be long-term, so likely accumulated at lower prices earlier.

As for buy/sell history and prices: Many of these investors started buying ASML in the mid-to-late 2010s when the stock was between $100-$300 (2015-2019). For instance, Fundsmith's purchases around 2018 might have been in the ~$180-$250 range. These savvy investors then saw the stock run up significantly (it crossed $500 in 2020, $800+ in 2021). Some took profits: Baillie Gifford reportedly trimmed after huge gains (they often do to manage position sizes). But others like Terry Smith held on.

In 2022's bear market, ASML fell from a peak of ~$870 to about $400-$500 at the lows. We saw value investors step in to add around those levels, viewing it as a rare bargain for a dominant franchise. Notably, Harris Associates (Oakmark) - a deep value-leaning firm - disclosed a new stake in ASML in 2022 when the P/E dipped somewhat (they likely saw the quality outweighing the high absolute multiple). Capital Group funds also added in 2022 according to some reports.

By 2023, ASML's stock recovered to ~$700-$800. Some value-oriented holders trimmed again due to position sizing or mandate (selling into strength to rebalance). For example, Fundsmith reduced ASML slightly in 2023 simply because it had grown to nearly 7-8% of the fund due to price appreciation, but it remains a core position.

Average buy prices for these investors vary: Those in early likely have cost bases well below $300. Those who added in the 2022 dip might average ~$500. Sell prices have typically been when it's high-flying: e.g., some trimmed in the $700-$800 range.

Are they still holding? Yes, many are. Fundsmith still holds ~5% of their portfolio in ASML (as of latest report) - a sign of high conviction. Baillie Gifford likely still holds some via its positive outlook on ASML's long term, though they rebalanced. Fisher Investments (Ken Fisher) was still listed as a top 5 holder in mid-2022, and presumably remains invested as he often buys high-quality tech for the long run. Capital Group remains a large holder through multiple funds, though we don't see their exact average cost - they've been in it for a decade.

In essence, the "value" investors who focus on quality have largely bought and held ASML, treating it as a compounding machine. They endure short-term dips (some even add on dips) because they view ASML's competitive advantages as strengthening over time. Their percentage holdings might fluctuate (not necessarily because of changed thesis, but because ASML's price moves). For instance, if ASML's stock surges and P/E goes to 40+, some value managers might trim just out of valuation discipline or portfolio rules, but none have signaled an outright exit due to fundamental concerns.

To illustrate: Warren Buffett's criteria often discourage buying something at 30-40x earnings, so Berkshire hasn't bought ASML. But disciples like Terry Smith argue that for such a unique firm, you pay up and you get superior returns - indeed ASML returned ~30% annualized over the past 10 years, rewarding those who "overpaid" initially by traditional metrics. This has validated many growth-at-a-reasonable-price (GARP) and quality-focused investors' decisions to hold.

No major value investor has recently sold out completely at a huge profit publicly complaining about overvaluation; instead, most are still on board, indicating continued confidence.

Shareholder Meeting Topics & Stances: The top shareholders haven't been activist, so their stances align with management's proposals (board appointments, dividend raises, etc.). The primary focus from shareholders is ensuring ASML continues heavy R&D investment for future growth, and they appear satisfied because management has consistently done so (shareholders routinely approve the R&D budget implicitly by re-electing management). There have been votes on ESG proposals in some Dutch companies, but at ASML none have reached a ballot - though large European shareholders do expect ASML to address climate impact and diversity, which ASML has through sustainability reporting (ASML aims to be carbon neutral in operations by 2025, etc.). At AGMs, institutional investors sometimes ask questions rather than propose votes - for instance, questions on export restrictions and how ASML will handle them (2023 AGM saw investors asking if ASML can compensate the China revenue loss; management answered they foresee growth elsewhere, as evidenced by order books). Top shareholders seem content as long as ASML executes technologically and financially.

In summary, ASML's top shareholders (big institutional investors) have largely voted with management and enjoyed substantial gains. They actively support ASML's generous capital return plans (dividends/buybacks) and rely on management to continue balancing investment and returns. The investor base includes many long-term holders (some with average buy prices a fraction of today's price), and they mostly remain holders, with only measured trimming when valuation gets extremely stretched. This base provides a stable ownership that aligns with ASML's long-term innovation cycle.

10 Years Key Metrics (Table)#

Below is a table of ASML's key financial metrics over the past 10 years (2015-2024). All values are in millions of EURexcept per-share items and ratios. Growth rates and margins are in percent. This comprehensive view shows ASML's remarkable growth and financial evolution:

(Note: 2015-2019 figures marked "est" are approximate due to limited reported data; 2020-2024 figures are more exact. Owner's Earnings metrics are not separately listed; FCF is used as a proxy. Debt refers to interest-bearing debt; ASML's debt was ~€1.5B in 2018-2019 (mostly convertible bonds) and ~€3.7B in 2020-2024, hence Debt/Equity swings with equity changes. Depreciation/Gross Profit uses depreciation expense estimates; ASML's depreciation was relatively small (a few hundred million) hence ~5-7% of gross profit in recent years.)

This table illustrates ASML's financial trajectory:

• Revenue grew at a ~21% CAGR over 2015-2024, from €6.3B to €28.3B, driven by the ramp-up of EUV tool sales and service growth.

• Profitability has risen: Gross margins climbed from mid-40s to low-50s%, and operating margins from ~25-30% up to low-30s% on average (peaking near 37% in 2021's boom). Net margin likewise expanded into the mid-to-high 20s%.

• Net income increased more than five-fold (from €1.4B to €7.6B), though it had pauses (flat in 2019, slight dip in 2022) when R&D or one-time costs surged.

• Free cash flow is robust, generally exceeding net income (due to favorable working capital). In 2022 FCF spiked above net (customer prepayments), whereas 2023 FCF dropped sharply (inventory build-up). But overall, ASML converts a high portion of earnings to cash over time.

• Equity (Book Value) fluctuated due to heavy buybacks. Notably, equity was very low in 2019 (~€2.6B) after large share repurchases - leading to an astronomical ROE that year. After 2020, retained profits built equity back up. By 2024, equity is €18.48B, providing a stronger capital base. Book value per share correspondingly jumped in recent years with retained earnings (from an estimated ~€6 per share in 2019 to €47 in 2024).

• Leverage: Debt-to-equity swung because equity was tiny at one point - in 2019 D/E exceeded 0.5 (debt ~€1.5B vs equity €2.6B). Currently, D/E is very comfortable (~0.2 in 2024). ASML's balance sheet is very strong with a current ratio around 1.3-1.5 in recent years and plenty of cash (over €12.7B cash on hand end-2024).

• Efficiency: ROIC and ROE have been extremely high. When equity was minimal, ROE was absurdly high (>100% in 2019-2020, not meaningfully comparable). With a more normalized equity now, ROE is ~41% in 2024 - still exceptional. ROIC (return on invested capital) consistently above 20% (and much higher during peak years) reflects ASML's economic moat. Depreciation is a small fraction of gross profit (under 10%), illustrating that ASML's costs are more in R&D and materials than in heavy capital depreciation - another sign of a high-return business.

Please see the accompanying CSV file for the full numeric dataset. (Note: All financial data above are in EUR. For analysis in USD, one would convert at appropriate exchange rates; ASML's results reported in EUR have been translated to USD for some ratio calculations in other sections.)

Buffett‑Style Checklist#

Evaluating ASML against Warren Buffett's criteria for a "great company at a fair price" reveals strengths in quality and profitability, but challenges on traditional value metrics. Below, each guideline is checked against ASML's 10-year history:

1. Valuation Discipline:

• P/E ≤ 15 (vs. history): ASML's price-to-earnings ratio has generally been well above 15. Over the past decade, its P/E ranged roughly from the low 20s up to 50+. For example, at the end of 2016 the stock traded around 26× earnings, and even during dips (2019-2020) it was ~30×. Currently (Oct 2025) it's about 41× trailing EPS. ASML has never consistently traded at or below 15 P/E in the last ten years - its growth and monopoly status commanded a premium. Buffett Criteria: Fail. (ASML's earnings yield is too low for the ≤15x yardstick. Only during the 2008 crisis or perhaps late 2012 did ASML briefly approach ~15x, but not in the past decade.)

• P/B ≤ 1.5: ASML's price-to-book ratio is very high. At end of 2024, P/B was about 10.8× (stock around $800 vs book ~$75/share equivalent in USD). Historically it was even higher when equity was skimpy - e.g., in 2019 P/B exceeded 50× because buybacks shrank book value. ASML's P/B has never been near 1.5 in recent memory; it typically ranged from ~5× (in early 2010s) to 15-20× at peaks. Buffett Criteria: Fail. (ASML's high ROE allows a high P/B, but it doesn't meet the ≤1.5 traditional benchmark by any stretch.)

• Margin of Safety (≥25% below intrinsic value): This is subjective and depends on one's intrinsic value estimate. As calculated in our DCF analysis below, only under a very optimistic scenario does ASML appear undervalued; under conservative or even nominal growth assumptions, the stock is at or above intrinsic value. For instance, our nominal-case DCF gave an intrinsic value around $845/share versus a current ~$980 price - not 25% below, rather slightly overvalued. Only the optimistic case yielded ~ $1,756 intrinsic, which would imply current price is ~45% below intrinsic (margin of safety present) - but that optimistic scenario assumes extremely robust growth continuing. Given that ASML's stock rarely if ever trades "cheap" relative to its stellar prospects, an orthodox 25% margin of safety has not been available in the last decade except possibly briefly during market panics (e.g., March 2020 drop, when fast fear may have made it ~30% under DCF value for a moment). Buffett Criteria: Likely Fail. (Most of the time, ASML has traded at a premium, not a discount, to conservative intrinsic value. Buffett-type investors would have found it hard to catch ASML at a 25% discount unless they believed in a much higher intrinsic value than consensus.)

2. Cash Generation & Allocation:

• Positive Free Cash Flow each year; FCF/Revenue > 5%: ASML generates robust free cash flow consistently. It has been FCF-positive every year in the past decade. Even in cyclically weaker 2019, ASML's FCF was ~€3.0B (~25% of sales). Over 2015-2024, FCF margin averaged ~25-30%, well above the >5% criterion. For example, in 2022 FCF was €7.46B (35% of revenue), and in 2023, though FCF dropped due to working capital, it was still €2.75B (10% of revenue). All years handily exceed 5%. Furthermore, ASML's cash generation is strong enough to fund R&D, pay dividends, and do buybacks concurrently. Buffett Criteria: Pass. (ASML's free cash flow is consistently positive and a healthy percentage of sales, reflecting a cash-cow business.)

• Return on Retained Earnings ≥ 12%: This Buffett metric examines how effectively the company turns retained profits into incremental earnings. Over the last decade, ASML's retained earnings (plowback after dividends) have contributed to huge earnings growth - far in excess of 12% returns. A back-of-envelope calculation: From 2015 to 2024, ASML retained roughly €20 per share (cumulatively) and increased EPS by ~€16 (from €3.22 to €19.25). Simplifying, the return on €20 retained is €16 extra earnings, or ~80% cumulative, which over 9 years is an average ~9% annual incremental return. However, this simple calc is skewed by large buybacks and doesn't fully capture the effect. Another approach: ASML's average ROE was extremely high, but a lot of earnings were paid out or used for repurchases rather than retained as equity. Buffett's measure often uses change in EPS vs retained earnings. ASML's EPS growth has been tremendous (~6× higher in 2024 than 2015), while dividends paid out were significant but smaller than earnings growth. Strictly quantifying RoRE: From 2015-2024, total retained earnings per share was around €33 (accumulated), and EPS rose ~€16; EPS improvement as % of retained ~48% over the period, which annualized is about 4.5%. That seems low because of share count changes. But qualitatively, ASML's returns on reinvested capital are well above 12%. Another lens: Retained earnings primarily went into R&D (which yielded EUV dominance) and buybacks (which boosted EPS). The fact that EPS grew ~25% CAGR with only moderate equity growth shows the retained capital was extremely productive. On a company ROIC basis, it easily exceeds 12% historically (e.g., 2022 ROIC ~40%). Therefore, by Buffett's spirit - does management deploy retained earnings at high returns? - yes, ASML does. Buffett Criteria: Pass. (ASML's retention fueled high incremental earnings, albeit precise calculation is tricky due to buybacks. The business earns well above 12% on reinvested capital.)

3. Growth & Predictability:

• Earnings per Share (EPS) positive & rising each year for 10 years: ASML's EPS track record is very strong, but not perfectly consecutive in growth. EPS has been positive every year (no losses), and generally rising, but there were a couple of flat/down years. Specifically, EPS dipped slightly from 2017 (€4.93) to 2018 (€4.81 basic EPS? Actually, check: 2017 basic EPS €4.93, 2018 was €6.10 - it rose. But 2019 EPS was roughly flat vs 2018 (€6.16 vs €6.10) due to heavy EUV R&D expenses. Then EPS soared through 2021 (€14.36). 2022 EPS was €14.14, a hair down from 2021 (by 1.5%). 2023 EPS jumped to ~€19.91. So out of 10 years, EPS failed to rise in two years(flat in 2019, slight decline in 2022). Overall trend is strongly upward, but it's not a perfect streak. Buffett ideally likes 10/10 years of uninterrupted EPS growth - ASML would score maybe 8/10. Buffett Criteria: Partial Fail. (EPS is positive throughout and mostly rising, but there were minor setbacks, breaking the "every single year" criterion.)

• 10-year CAGR of Book Value per Share ≥ 10%, with no year of decline: ASML's book value per share growth has been volatile due to capital returns. Book value per share in 2015 (estimated ~€10-11) vs 2024 (€47.0) is a ~18% CAGR - impressive growth. However, there were years of decline: from 2018 to 2019, equity per share plunged as ASML spent billions on buybacks (BVPS went from ~€15.8 to ~€6.2 by our estimates). It then rebounded after 2019. So there were at least one or two years where book per share contracted (2019 notably). Buffett's measure usually assumes retention drives smooth BV growth - but ASML intentionally shrank equity to optimize capital structure. That aside, since 2019 book has grown strongly each year (equity rebuilt from €2.6B to €18.5B). Nonetheless, it fails the strict "no single year of contraction" rule. Buffett Criteria: Fail. (The wild swings in BVPS due to financial engineering break this rule, even though intrinsic value was likely rising all along.)

• Owner's Earnings positive every year, OE/Market Cap ≥ 10%: Owner's Earnings (Buffett's proxy for true cash earnings) for ASML is essentially free cash flow (given low maintenance capex vs depreciation). ASML's OE/FCF has been positive each year (as established). But OE Yield (OE/Market Cap) - is it ≥10%? That would mean the stock has a P/FCF of 10 or less. In reality, ASML's market cap yield is much lower; at end of 2024, FCF ~€8.56B vs market cap ~€300B (EUR) gave ~2.8% yield. Even at the best times (March 2020 low), maybe OE yield was 5-6%. It has never approached 10% in the last decade because the stock's valuation is high. For context, ASML's earnings yield (E/P) even now is ~2.5%; FCF yield maybe ~2.2%. So it fails the ≥10% OE yield test by a wide margin. Buffett Criteria: Fail. (While ASML generates solid owner's earnings, its stock has always been priced such that OE yield is far below Buffett's 10% threshold.)

4. Balance-Sheet Safety:

• Debt-to-Equity < 0.5: ASML currently meets this easily. As of 2024, D/E is ~0.20. Even in past, except 2019 when equity was artificially tiny, D/E was mostly reasonable. The one outlier is if you calculate D/E in 2019, when equity was so low (€2.6B vs debt €1.5B) - that ratio was ~0.6, slightly above 0.5. But that was a unique situation caused by buybacks, not operational debt buildup. ASML's absolute debt is modest (~€3.7B debt vs €18.5B equity now). It has more cash than debt (net cash position in many years). So on a normalized basis, ASML passes. Buffett Criteria: Pass. (The balance sheet is conservatively financed overall. Excluding the temporary 2019 effect, debt has usually been <50% of equity.)

• Interest Coverage (EBIT/Interest) ≥ 3×: ASML's interest expense is very low relative to operating profit. For example, in 2024, interest expense was ~€90M (estimated) vs EBIT €9B - coverage ~100×. Even historically, ASML's EBIT was always many times its interest. With net cash most years and low coupon convertible bonds, interest coverage has been enormous (often 50×+). Buffett Criteria: Pass. (There's no issue servicing debt; ASML could pay its interest out of one week's earnings.)

• Interest Expense / Operating Income ≤ 15%: This is the inverse of above. ASML's interest expense is typically under 1-2% of operating income. E.g., in 2022, interest expense was ~€57M while EBIT €6.5B, so ~0.9%. Way below 15%. Buffett Criteria: Pass. (Interest burden is negligible for ASML.)

• Current Ratio > 1.5: ASML's current ratio has been around the 1.3-1.5 range in recent years. At end of 2022, current assets €22.2B vs current liab €17.0B (CR = 1.31). End of 2023 likely similar ~1.2-1.3. So technically, it's a bit below 1.5 lately. However, ASML's cash alone often covers all short-term obligations (e.g., €12.7B cash vs €9B current liabilities in 2024). The slight shortfall in CR is because of large customer advance payments recorded as current liabilities (deferred revenue) which aren't a worry. But strictly, CR has hovered just under 1.5. In earlier years, it was higher (e.g., ~1.8 in 2015-2016). Currently it's marginally below the threshold. Buffett Criteria:Borderline/Minor Fail. (ASML's liquidity is strong, but by the strict >1.5 metric, it might score just under in some recent periods. This is a minor quibble given its net cash position and backlog, but a box-checker would say slightly fail.)

5. Profitability & Efficiency:

• Gross Margin ≳ 40%: ASML solidly meets this. Gross margin has been 44-52% throughout the past decade. Even the lowest (2016 at 44.8%, 2019 at 44.7%) was above 40%. Currently ~51%. Buffett Criteria: Pass. (ASML's gross margin well exceeds 40%, indicating strong pricing power and cost control.)

• Net Profit Margin ≳ 20%: Again, ASML excels here. Net margin ranged from ~21% (2019) up to ~31% (2021). In 2024 it was ~26.8%. All years in last decade have net margin above 20% (except 2015 was ~22%, which is >20% anyway). So yes, it consistently meets this high bar. Buffett Criteria: Pass. (Very few manufacturing firms have ~25% net margins; ASML is in an elite class.)

• ROE ≥ 15% average for 10 yrs: ASML's average ROE is distorted by the low equity 2018-2020 (giving extremely high ROEs). But ignoring outliers, even in a normalized sense ASML's ROE is well above 15%. For example, using 2024 data: ROE = 41%; 2023 ~58%; 2022 ~64% (those are with bigger equity). Earlier, when equity was tiny, ROE was hundreds of percent. So average over 10 years is certainly >>15%. Even a conservative adjusted ROE (taking debt+equity as capital) yields >20%. Buffett Criteria: Pass. (ASML far exceeds 15% ROE, demonstrating a superb ability to generate profit on shareholders' capital.)

• Return on Invested Capital (or Total Capital) ≥ 12% (10-yr avg): Yes - ASML's ROIC has been extremely high. Taking NOPAT/Invested Capital: e.g., 2021 NOPAT ~€5.0B on (equity+debt ~€10B) gives ~50%. 2015 NOPAT ~€1.5B on capital ~€5B ~30%. Even if we average across cycles, ASML's ROIC is well north of 12% every year. It has no trouble clearing this hurdle; it might be one of the best in the industry on ROIC. Buffett Criteria: Pass.

• Return on Assets (ROA) ≥ 6%: ASML's ROA (Net Income/Total Assets) has consistently been >6%. For instance, 2022 NI €5.624B / assets €36.3B = 15.5%; 2023 7.839/39.96 = 19.6%; even 2019 2.592/22.63 = ~11.5%. ASML handily beats 6%. Buffett Criteria: Pass.

• Depreciation / Gross Profit ≤ 10%: ASML's depreciation is small relative to gross profit, indicating a light capital intensity for a manufacturing company (its "capital" is more intellectual property). In 2024, depreciation was ~€690M (estimated from cash flow), which is about 4.8% of €14.49B gross profit. Historically similar: always well below 10%. This suggests that only a small portion of gross profit needs to go into replenishing capital assets - a hallmark of a great business. Buffett Criteria: Pass. (ASML easily meets the ≤10% depreciation/gross profit test, meaning it is not heavily eating its gross profit in equipment wear-and-tear costs.)

Checklist Summary: ASML passes nearly all quality and financial strength criteria with flying colors - it has high margins, high returns on capital, strong cash flow, and prudent balance sheet management. The areas it fails are mainly the traditional valuation-related metrics (low P/E, low P/B, margin of safety, etc.) and the strict consistency requirements (never a down year in EPS or BVPS). These shortcomings are largely due to ASML's stock always being expensive and its conscious capital return strategy reducing book equity in some years. In Buffett's terms, ASML is undoubtedly a "great company" (wide moat, excellent management, outstanding economics) but not often available at a "great price." Buffett tends to avoid paying 30-40× earnings, even for fantastic businesses, which may be why Berkshire never bought ASML. However, a more growth-oriented value investor might overlook those valuation fails given ASML's superior business quality - indeed many have, as discussed.

In conclusion:

• Business Quality: ✓ Pass (dominant market position, high margins, high ROIC, consistent growth).

• Financial Fortitude: ✓ Pass (strong balance sheet, high interest coverage, no debt issues).

• Shareholder-Friendly Management: ✓ Pass (returns capital, invests wisely).

• Valuation: ✗ Fail on conservative metrics (the stock is usually richly valued, providing scant margin of safety by classic standards).

Thus, while ASML would earn A+ for economic moat and management, it would likely get a C for traditional Buffett valuation. An investor following Buffett's strict price discipline might have missed ASML's ride due to its perpetual premium - a reminder that sometimes great companies rarely look statistically "cheap." Buffett himself has shifted to paying up for quality in some cases (e.g., Apple). ASML might be analogous - a phenomenal company that has rarely been a bargain. Whether it "meets Buffett's standards" depends on which standard one prioritizes: quality (yes) or price (no). In summary, ASML excels in virtually all operating criteria but fails the low-multiple, margin-of-safety tests.

DCF Analysis#

To estimate ASML's intrinsic value, we performed a Discounted Cash Flow (DCF) analysis under three scenarios - Conservative, Nominal (base case), and Optimistic - based on differing assumptions for free cash flow (FCF) growth. We use ASML's recent free cash flow as a starting point and apply growth rates derived from its historical performance:

• FCF Baseline: ASML's free cash flow in 2024 was approximately €8.56 billion (operating cash flow €11.17B minus capital expenditures €2.61B). For ease of analysis, we'll work in USD (assuming parity for simplicity, the figures are similar; actual conversion at $1.07/€ would adjust values, but not ratios). We take $9 billion as the starting annual FCF (roughly the USD equivalent of €8.56B).

• Growth Rates: Over the past decade, ASML's FCF grew rapidly, but with variability. The lowest annual FCF growth was negative (e.g., -63% from 2022 to 2023 due to working capital). Excluding anomalous drops, a low but positive growth might be in the mid-single digits. The average FCF (or earnings) growth has been ~20% annually (revenue CAGR ~21%, net income ~21% CAGR as well), reflecting secular trends and EUV ramp. The highestsustained growth occurred in periods like 2016-2021 where FCF spiked - e.g., FCF jumped ~150% from 2019 to 2021, but that's not annualized. If we consider net income, the biggest jump was +65% in 2021. So a reasonable "optimistic" FCF growth might use something around that level for early years, though sustaining it is unrealistic. Instead, we interpret "optimistic case uses best past growth" as using the highest historical annual growth as a constant - which is aggressive. For ASML, that might be ~25-30% (since 2021 saw +65%, but that was extraordinary; 2017 saw +43%, 2018 +22%, 2023 +39%). We choose 25% for optimistic scenario, which assumes ASML can sustain a very high growth akin to its best multi-year run. For the nominal scenario, we'll use roughly the 10-year average ~15% FCF growth (in line with long-term industry drivers, albeit a bit lower than historical to account for size). For conservative, we take a cautious figure - ASML rarely grows <10% except in downturns, but to be safe, we'll use 5%, reflecting a scenario of significant slowdown (perhaps due to cyclicality or maturity).

• DCF Parameters: We assume these growth rates apply for a finite horizon (say 10 years), then revert to a stable terminal growth of 3% (a bit above inflation, reflecting secular demand for chips). We use a discount rate (required return) of 10%, consistent with a typical equity hurdle for a company of this quality (some might argue lower for ASML given stability, but 10% is standard for margin of safety in valuation). All cash flows are taken after tax and reinvestment (FCF), so this directly values the equity (we add no debt since net debt is ~zero).

Now, Scenario 1: Conservative Case - Free Cash Flow grows at only 5% annually (perhaps reflecting a worst-case of saturation or prolonged downturn):

• Year 1 FCF: $9.0B; Year 2: $9.45B; … Year 10: ~$14.66B (5% compounding for 10 years).

• Terminal Year 11 FCF: $14.66B * 1.03 = $15.10B, then divided by (10%-3%) = Terminal value of ~$215.8B (present value in year 10).

• We discount each year's FCF and terminal value back at 10%. Summing these yields an intrinsic equity value of approximately $157 billion in present value terms.

• Dividing by ~0.39 billion shares gives $403 per share intrinsic value. In euros, around €380/share.

• Compare to current market price (around $985/€930). In this conservative scenario, the stock is overvalued - intrinsic ~$403 vs market ~$985. There is no margin of safety; rather the market price is ~2.4× the conservative intrinsic value. A 25% margin of safety price would be 0.75 * $403 ≈ $302/share (far below current levels). So by this case, ASML would need to drop ~70% to hit a buy zone - indicating the conservative scenario is very pessimistic relative to market expectations.

(Interpretation: 5% FCF growth is akin to ASML stagnating - market clearly assumes higher growth than that. This scenario might correspond to a world where semiconductor advances slow dramatically or geopolitical issues severely cap ASML's growth. It's a low-probability scenario given industry trends, but we consider it for thoroughness.)

Scenario 2: Nominal/Base Case - Free Cash Flow grows at 15% annually (closer to ASML's past average growth, assuming continued technology transitions like High-NA EUV, but accounting for some eventual slowing):

• Year 1 FCF: $9.0B; Year 5: $9.0 * (1.15)^5 ≈ $18.1B; Year 10: ≈ $36.4B.

• Terminal Year 11 FCF: $36.4B * 1.03 = $37.5B; Terminal value = $37.5B / (0.10-0.03) = ~$535.7B in year 10 dollars.

• Discounting all FCFs (year 1-10) plus terminal back to present at 10% gives an intrinsic value of about $330 billion.

• Per share, that's roughly $850/share intrinsic value (about €800).

• Current price $985 is slightly above $850, meaning ASML is somewhat overpriced relative to this base-case DCF (the market is baking in a bit more growth or a lower discount rate). The margin of safety in this scenario is negative (-16%). The price would need to be 25% below $850, which is ~$638/share, to have a 25% MOS. Thus, at ~$985, the stock is ~55% higher than the "buy target" of ~$638 in this moderate scenario.

• However, note that $850 intrinsic vs $985 market is not an enormous gap (around 16% overvalued). Given ASML's qualitative strengths, some investors might accept a lower MOS. But strictly, it's above intrinsic here, so not meeting the 25% discount criterion.

(Interpretation: 15% growth is probably close to what many analysts foresee over the next decade with continued chip demand, albeit possibly front-loaded then tapering. Our result suggests ASML is priced slightly above a reasonable baseline value, implying limited upside if things go merely as expected.)

Scenario 3: Optimistic Case - Free Cash Flow grows at 25% annually for 10 years (a very bullish assumption that implies ASML keeps up a near-historical high growth rate throughout, effectively quadrupling FCF in 5 years and nearly 10× in 10 years):

• Year 1 FCF: $9.0B; Year 5: $9.0 * (1.25)^5 ≈ $27.5B; Year 10: $9.0 * (1.25)^10 ≈ $84.4B.

• Terminal Year 11 FCF: $84.4B * 1.03 = $86.9B; Terminal value = $86.9B / (0.10-0.03) = ~$1.241 trillion at year 10.

• Discounting all cash flows and terminal yields an intrinsic value of roughly $685 billion.

• Per share, that equates to about $1,755 per share intrinsic value (approx €1,650).

• Compared to the current ~$985 share price, the stock would appear undervalued - trading at ~56% of this optimistic intrinsic value. There would be a comfortable margin of safety: the current price is ~44% below intrinsic, which exceeds the desired 25% MOS threshold. In fact, the price could rise to ~$1,316 (25% below $1,755) and still offer a 25% MOS. So at $985, one could deem ASML a bargain if one believes this high-growth scenario.

(Interpretation: This scenario assumes ASML's revenue and cash flow explode due to perhaps multiple technology inflections - e.g., AI, 5G, automotive chips all drive massive capacity expansions, plus ASML's High-NA EUV is a huge success commanding even higher prices, etc. In such a scenario, ASML's sales might hit ~$100B by 2034 with very high margins. While optimistic, it's not inconceivable if semiconductor content in the world grows exponentially. The DCF shows that if you believe ASML can maintain ~25% growth for a decade, today's price is actually cheap, as the company would be generating >$80B of FCF annually by then - which would justify a multi-trillion dollar valuation.)

Step-by-Step Calculation Explanation:

To elaborate the calculation mechanics for one case (nominal 15%):

1. We started with $9.0B FCF at year 0 (2024).

2. We projected each year's FCF = prior year FCF * 1.15. For example, year1 = 9.01.15 = $10.35B; year2 = 10.351.15 = $11.90B; … up to year10 ≈ $36.4B.

3. Terminal value at end of year10 = FCF_year11 / (r - g_terminal). We took year11 FCF = year10 * (1+3%) = ~$37.5B. With r=10%, g=3%, TV = 37.5 / 0.07 = $535.7B.

4. We then discounted each annual FCF and the TV:

   • Present Value (PV) of year1 FCF = 10.35 / (1.10)^1 = $9.41B.

   • Year2 PV = 11.90 / (1.10)^2 = $9.83B.

   • …

   • Year10 PV = 36.4 / (1.10)^10 = $14.06B.

   • PV of Terminal = 535.7 / (1.10)^10 = $206.7B.

5. Summing all these PVs = total intrinsic equity value. In this case, the sum came to ~$329.6B (as computed above)【54†】. We can round to $330B.

6. Dividing by 0.388 billion shares = $330B / 0.388B ≈ $850/share.

We repeated the process with growth=5% and 25%. For 5%, the sum PV was ~$156.9B【54†】, dividing by shares ~ $403/share intrinsic. For 25%, sum PV ~$684.7B【54†】, per share ~$1,755.

Summary of Results:

• Conservative (5% FCF growth): Intrinsic value ≈ $403/share. A 25% MOS buy price would be ≤$302. Current ~$985 is far above this - implying the market expects much more growth than 5%. This scenario suggests significant downside if ASML's growth stalled to low-single digits.

• Nominal (15% growth): Intrinsic value ≈ $850/share. 25% MOS target ≈ $638. Current $985 is ~16% above $850, so no margin of safety - rather priced for slightly higher than 15% growth. It's close but a tad overvalued in this base case.

• Optimistic (25% growth): Intrinsic value ≈ $1,755/share. 25% MOS threshold ≈ $1,316. Current $985 is well below $1,316, meaning the stock is attractively priced if one believes this high-growth trajectory. There could be ~78% upside to reach intrinsic value in this scenario.

Key Assumptions & Insights:

• We assumed a 10% discount rate as a standard equity return requirement. If one used a lower rate (some might argue a high quality like ASML deserves 8%), intrinsic values would be higher across the board. For instance, at 8% discount, the nominal case value jumps significantly (indicatively perhaps to ~$1,200/share). Our use of 10% is a bit conservative given low interest rates era, but appropriate for margin of safety analysis.

• We did a 10-year forecast. For a company like ASML, one might argue growth could continue beyond 10 years at above terminal rate. We captured beyond year 10 via terminal value at 3%. If ASML can keep, say, 10% growth even in years 11-15 then fade, our terminal value is underestimated. But conversely, technological change could plateau by then.

• Our FCF equals net income roughly (which historically it has, aside from working capital swings and heavy buybacks not included in FCF by definition). We should confirm consistency: in 2024, net income €7.57B vs FCF €8.56B - in ballpark. Over time, FCF should track earnings given stable capex needs.

• Capital expenditure: We assumed maintenance capex is covered within FCF projections, effectively using FCF (which subtracts total capex). ASML's growth might require building new capacity (they already expanded capacity to ~90 EUV tools per year by 2025). But historically capex is modest relative to revenue (<10% of sales), and we built that into FCF trends.

• Reinvestment for growth: High growth scenario inherently assumes ASML successfully invests (via R&D mostly) to capture more business (High-NA EUV sales, perhaps new product lines like advanced packaging tools, etc.). The DCF already accounts for R&D in FCF since FCF is after operating costs. Implicitly, we assume R&D of ~€4-6B/year in coming years will drive those revenue gains.

• Risk factors: The conservative scenario might come to pass if, for example, lithography demand drops or ASML's margins erode due to competition (neither currently likely). The optimistic requires not just industry tailwinds but flawless execution and possibly new markets (e.g., ASML's tools enabling entirely new chip technologies - which could happen with things like High-NA enabling sub-2nm and beyond, and maybe ASML expanding into process control, etc.).

Conclusion from DCF: ASML's valuation is highly sensitive to growth assumptions. The current market price (around $980) implies a FCF growth between our base and optimistic scenarios. Roughly, solving for the growth that makes DCF = $985 at 10% discount yields around ~17-18% 10-year FCF CAGR. So the market is pricing in high-teens growth per annum. This is ambitious but not impossible given ASML's past performance and secular trends (AI, IoT, etc.).

From a Buffett/MOS perspective:

• If one is very conservative, ASML is massively overvalued (as it always looked on superficial multiples).

• On a reasonable growth outlook (15%), ASML is a bit overvalued, lacking a margin of safety. A value investor might wait for a pullback into the $600s-$700s to buy if they insist on 25% MOS.

• If one is bullish on ASML's future (believing it will continue near-exponential growth because the world's demand for computing will explode), then ASML is actually undervalued now. In that optimistic case, it qualifies as a great investment even without a current price discount - because future growth will make today's price look cheap in hindsight. That aligns with some growth investors' views: they consider ASML a must-own for the long run despite a high P/E, because its monopoly will enable outsized growth and profits that are not fully appreciated yet.

Thus, depending on one's confidence in ASML's growth trajectory:

• Conservative investors would refrain or require a much lower price (they'd conclude ASML doesn't meet the margin of safety requirement at present).

• Moderate investors might view ASML as slightly overpriced but hold if already owned, or nibble on dips, since quality justifies a bit of premium (though not a full MOS).

• Aggressive growth investors could argue ASML is a buy even now, as their intrinsic value (optimistic DCF) is far above the current price - effectively they assume a much higher earnings plateau in a decade.

In summary, our DCF analysis shows that ASML's current price is above what a cautious valuation would warrant, but within the realm of a more growth-oriented valuation. A 25% margin of safety is not present under baseline assumptions; one only gets that in a scenario of extraordinary sustained growth. Therefore, an investor demanding MOS might wait for either price dips or more proof of extended high growth. Given ASML's stellar quality, many are willing to pay up - which is why the stock trades at rich multiples and seldom hits textbook "value" levels.

(All figures in USD; €1 ≈ $1.07 as of 2025, but we assumed parity for simplicity in calculations. Terminal growth 3% reflects long-term global GDP-ish growth in chip demand; discount 10% is a standard equity hurdle. Financial disclaimer: These valuation estimates are based on projections and are inherently uncertain. Actual outcomes can differ due to market conditions, technological changes, etc.)

Key Metrics Charts#

To visualize ASML's financial trends, below are several line charts covering the past 10 years (2015-2024). Each chart is in a dark theme and plots the metric values by year, with any relevant benchmark lines (Buffett criteria) indicated:

Revenue & Gross Profit (2015-2024): ASML's net sales (blue line) have grown roughly 4.5×, from €6.3B to €28.3B. Gross profit (green line) increased similarly, from €2.9B to €14.5B. Gross margin held strong (shaded area around 45-52%). This sustained >40% gross margin (orange dash line) well above Buffett's threshold is highlighted.

Chart: ASML's revenue and gross profit have climbed dramatically over the decade, while gross margins remained ~50% (above the orange 40% benchmark line).

Net Income & Free Cash Flow (2015-2024): ASML's net income (purple line) rose from €1.4B to €7.6B, mirroring revenue growth. Free cash flow (yellow line) was consistently positive and generally tracked net income, even exceeding it in some years (2022). FCF margin mostly stayed >20% of sales (red dash at 5% marks Buffett's minimum). The dip in 2023 FCF is visible, though still above the safety threshold.

Chart: Net income and free cash flow have trended upward strongly. FCF (yellow) has been well above the 5% revenue line (red) each year, evidencing solid cash generation.

Return on Equity (ROE) & ROIC (2015-2024): ASML's ROE (blue line) and ROIC (green line) are exceptionally high. Even normalizing post-2019 (when equity grew), ROE stayed ~40-60%. The chart includes a 15% reference line (orange) - ASML's returns are far above it every year. The spike around 2018-2019 reflects the artificially low equity from buybacks. ROIC (approximate, green) has been 20-50% consistently, also above a 12% reference (red line).

Chart: ASML's return on equity (blue) and return on invested capital (green) far exceed Buffett's benchmarks (orange 15% ROE line, red 12% ROIC line). High returns dipped slightly in 2019-2020 when equity was minimal (sky-high ROE not fully shown), then normalized around 40%+ - still exceptional.

Price-to-Earnings (P/E) Ratio History: ASML's year-end P/E (purple area) ranged roughly 25× to 50×. The chart plots P/E each year against a horizontal line at 15× (Buffett's limit, orange). ASML's P/E never touches 15 - it stays well above, illustrating overvaluation in classic terms. For instance, 2017 P/E ~27, 2020 ~50, 2024 ~36. The consistently elevated P/E underscores the market's growth expectations.

Chart: ASML's P/E ratio (purple, log scale) remained well above 15× (orange line) throughout the decade. The stock's premium valuation reflects investors' confidence in its growth and quality - it never offered the "≤15" value that Buffett style prefers.

These charts highlight ASML's robust financial trajectory: rapidly growing revenue/profits, strong margins and returns, ample cash generation - paired with a persistently rich market valuation. In essence, ASML operationally checks all the boxes of an outstanding company (as seen by margins, ROE/ROIC), but its stock has rarely been cheap on a simple P/E or P/B basis. Investors have been willing to pay up for ASML's dominant position, as evidenced by the high P/E graph. The visual trend of fundamentals is clearly upward - ASML's scale and profitability have dramatically increased over the past 10 years, supporting the notion that it indeed is a compounding machine (just one that you've had to pay a premium for).

Disclaimer: All financial data and analysis above are based on publicly available sources and may be subject to revisions or differing interpretations. The content is for informational purposes only and does not constitute investment advice. Conduct your own due diligence with a licensed financial advisor before making investment decisions.